Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mupirocin, quantity: 20 mg/g - ointment - excipient ingredients: macrogol 3350; macrogol 400 - apo-mupirocin is indicated for the topical treatment of mild impetigo.

United States - English - NLM (National Library of Medicine)

biomes pharmaceuticals llc - mupirocin calcium (unii: rg38i2p540) (mupirocin - unii:d0gx863oa5) - mupirocin 2 g in 100 g - mupirocin cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin cream is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin cream. click here to enter use in specific populations pregnancy category b. there are no adequate and well-controlled studies of mupirocin cream (contains equivalent of 2% mupirocin free acid) in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. developmental toxicity studies have been performed with mupirocin administered subcutaneously to rats and rabbits at doses up to 160 mg per kg per day in both species. this dose is 22 and 43 times, respectively, the human topical dose (approximately 60 mg mupirocin per day) based on body su

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - mupirocin, quantity: 20 mg/g - ointment - excipient ingredients: macrogol 400; macrogol 3350 - mupirocin lupin is indicated for the topical treatment of mild impetigo.

United States - English - NLM (National Library of Medicine)

avpak - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to: s. aureus and s. pyogenes . this drug is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

United States - English - NLM (National Library of Medicine)

proficient rx lp - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to: s. aureus and s. pyogenes . this drug is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

United States - English - NLM (National Library of Medicine)

medsource pharmaceuticals - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to: s. aureus and s. pyogenes . this drug is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment 2% is indicated for the topical treatment of impetigo due to: staphylococcus aureus and streptococcus pyogenes . this drug is contraindicated in individuals with a history of sensitivity reactions to any of its components.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology ( 12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the est

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology ( 12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3) ]. no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the esti